Latest Research Reports

Recent failures in Alzheimer’s R&D

Recent failures in Alzheimer’s R&D

Report: Immune thrombocytopenia market to witness minimal growth at CAGR of 0.6% by 2025

The immune thrombocytopenia (ITP) market will witness minimal growth from $928m in 2015 to $985m by 2025, says a report by...

Report: Immune thrombocytopenia market to witness minimal growth at CAGR of 0.6% by 2025

Total Prevalent Cases of Dyslipidemia Expected to Grow Globally

Total Prevalent Cases of Dyslipidemia Expected to Grow Globally

Report: Rheumatoid arthritis market projected to reach $28.5bn by 2025

Introduction of interleukin (IL)-6 inhibitors is expected to drive growth in the rheumatoid arthritis space, according to a report by...

Report: Rheumatoid arthritis market projected to reach $28.5bn by 2025

C. difficile pipeline vaccines could offer an alternative to antibiotics

The incidence of Clostridium difficile has increased significantly over the last two decades, due in part to the emergence of new, hyper-virulent strains. In recent years it has surpassed MRSA...

C. difficile pipeline vaccines could offer an alternative to antibiotics

Novavax driving to achieve significant market presence in respiratory complications market

Novavax driving to achieve significant market presence in respiratory complications market

FDA approval of siliq for psoriasis – how will the drug perform in an already overcrowded market?

FDA approval of siliq for psoriasis – how will the drug perform in an already overcrowded market?

Report: Growth Expected in Dyslipidemia market to $29bn by 2025

Unmet needs in the dyslipidemia market are expected to provide manufacturers with new avenues for development, says a new report by...

Report: Growth Expected in Dyslipidemia market to $29bn by 2025

Development of PARP inhibitors for ovarian and breast cancer is equally extensive

A large number of clinical trials evaluating inhibitors of the enzyme poly ADP ribose polymerase (PARP) in breast and ovarian cancers are either ongoing or completed....

Development of PARP inhibitors for ovarian and breast cancer is equally extensive

Report: Partnerships between big pharma and small biotech to dominate Lupus R&D landscape

The global Lupus R&D landscape is expected to witness partnerships between big pharma and small biotech in the future, according to a report by...

Report: Partnerships between big pharma and small biotech to dominate Lupus R&D landscape

Targeted therapies will radically improve head and neck cancer treatment

Head and neck cancer (HNC) is the sixth most common cancer worldwide, and the majority of available treatments are highly toxic...

Targeted therapies will radically improve head and neck cancer treatment

Report: Lupus market to reach $3.2bn in value by 2025

The launch of new first-in-class products is expected to drive growth in the lupus market at a compound annual growth rate of 10.6%, according to a report by...

Report: Lupus market to reach $3.2bn in value by 2025

Amgen and Cytokinetics: moving forward with chronic heart failure therapy

In December, Amgen and Cytokinetics announced that they will be moving forward with their novel chronic heart failure therapy, omecamtiv mecarbil, with the launch of their Phase III...

Amgen and Cytokinetics: moving forward with chronic heart failure therapy

FDA approves Eucrisa, first-in-class PDE4 inhibitor for atopic dermatitis

On December 14 2016, Pfizer announced the FDA approval of Eucrisa (crisaborole) ointment 2%, a non-steroidal topical phosphodiesterase-4 (PDE4) inhibitor, for the treatment of mild to...

FDA approves Eucrisa, first-in-class PDE4 inhibitor for atopic dermatitis

FDA approves first new drug for Atopic Dermatitis in over a decade

On December 14, 2016, Pfizer announced the FDA approval of Eucrisa (crisaborole) ointment 2%, a non-steroidal topical phosphodiesterase-4 (PDE4) inhibitor, for the treatment of mild to...

FDA approves first new drug for Atopic Dermatitis in over a decade

Report: Cancer immunotherapies market projected to grow fourfold to reach $75.8bn by 2022

The cancer immunotherapies market is projected to witness rapid growth at a compound annual growth rate (CAGR) of 23.9%, according to a report by GBI...

Report: Cancer immunotherapies market projected to grow fourfold to reach $75.8bn by 2022

Report: Type 2 diabetes drugs may help in alleviating Alzheimer’s disease symptoms

Research on type 2 diabetes mellitus (T2DM) drugs has revealed their potential in alleviating symptoms within Alzheimer’s disease patients, according to a report by GBI...

Report: Type 2 diabetes drugs may help in alleviating Alzheimer’s disease symptoms

Report: Smaller companies expected to increase presence in the influenza vaccines market

The seasonal influenza vaccines market is largely dominated by big pharmaceutical companies and expected to witness the entry of smaller companies, according to a report by...

Report: Smaller companies expected to increase presence in the influenza vaccines market

Report: Psoriatic arthritis market to reach $12.6bn by 2025

The psoriatic arthritis market is projected to grow from $4.53bn in 2015 to approximately $12.6bn by 2025 in the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK...

Report: Psoriatic arthritis market to reach $12.6bn by 2025

Report: Cannabinoid-based products emerging as promising pharmaceutical ingredients

The market for synthetic cannabinoid products is growing despite legal restrictions, says a white paper from GBI...

Report: Cannabinoid-based products emerging as promising pharmaceutical ingredients

Report: Alkermes’ ALKS-5461 to emerge as key player in major depressive disorder market

Positive results from a Phase III study on Alkermes’ ALKS-5461 shows promise towards the development of a new treatment for major depressive disorder (MDD), according to a report by...

Report: Alkermes’ ALKS-5461 to emerge as key player in major depressive disorder market